ArticleInternational journal of molecular sciences2026
Stage-Dependent Genetic Association of the TyG Index with Cardiovascular-Kidney-Metabolic Syndrome Severity: A Genome-Wide Association and Mendelian Randomization Study.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We aimed to determine whether the genetically predicted triglyceride-glucose (TyG) index, a surrogate marker of insulin resistance, is associated with cardiovascular-kidney-metabolic (CKM) stage severity and whether these associations are consistent with a potential causal role of insulin resistance within the CKM staging framework. The associations between the TyG index and CKM stages were assessed among 107,161 Taiwan Biobank participants using multivariable regression. CKM stages 3 and 4 were combined as the advanced CKM stage group. A genome-wide association study (GWAS) in 104,778 participants identified genetic determinants of the TyG index, followed by Mendelian randomization (MR), weighted genetic risk score (wGRS) analyses, and sample-split MR analyses. CKM stage severity was evaluated using ordinal regression analysis, a sensitivity analysis (CKM stages ≥ 1 vs. stage 0), and a later-stage comparison analysis (CKM stages ≥ 2 vs. stages 0-1). The TyG index increased progressively across CKM stages. GWAS identified 61 genome-wide significant loci associated with the TyG index. MR analyses demonstrated that genetically predicted TyG index was associated with greater CKM stage severity across all models, with consistent findings in the sample-split analyses. Genetic associations were modest for CKM stage 1 versus stage 0 but became substantially stronger for CKM stage 2 and the advanced CKM stages. Genetically predicted TyG index was associated with higher CKM stage severity in a stage-dependent manner, with substantially stronger genetic associations from CKM stage 2 onward. These findings are consistent with a potential causal role of insulin resistance in CKM stage severity and highlight the TyG index as a complementary biomarker for metabolic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.